C

Complete Dermatology | Sugar Land

Research site
(Unclaimed)
Location
7616 Branford Place Suite 240, Sugar Land, Texas, United States of America
Site insights

Top conditions

Atopic Dermatitis (4 trials)

Dermatitis (4 trials)

Eczema (3 trials)

Vitiligo (1 trial)

Top treatments

Lebrikizumab
PF-07264660
Amlitelimab
Ritlecitinib
Dupilumab
PF-07275315

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

5 of 5
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...

Enrolling
Atopic Dermatitis
Drug: Lebrikizumab

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participant...

Enrolling
Dermatitis Atopic
Drug: Amlitelimab
Drug: Topical corticosteroids

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Other: Placebo
Drug: PF-07264660

Trial sponsors

Lilly logo

Lilly (2 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems